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Drug therapeutic indications and side-effects are both measurable patient phenotype changes in
response to the treatment. Inferring potential drug therapeutic indications and identifying clinically
interesting drug side-effects are both important and challenging tasks. Previous studies have utilized
either chemical structures or protein targets to predict indications and side-effects. In this study, we com-
pared drug therapeutic indication prediction using various information including chemical structures,
protein targets and side-effects. We also compared drug side-effect prediction with various information
sources including chemical structures, protein targets and therapeutic indication. Prediction performance
based on 10-fold cross-validation demonstrates that drug side-effects and therapeutic indications are the
most predictive information source for each other. In addition, we extracted 6706 statistically signiﬁcant
indication-side-effect associations from all known drug-disease and drug-side-effect relationships. We
further developed a novel user interface that allows the user to interactively explore these associations
in the form of a dynamic bipartitie graph. Many relationship pairs provide explicit repositioning hypoth-
eses (e.g., drugs causing postural hypotension are potential candidates for hypertension) and clear
adverse-reaction watch lists (e.g., drugs for heart failure possibly cause impotence). All data sets and
highly correlated disease-side-effect relationships are available at http://astro.temple.edu/tua87106/
druganalysis.html.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Drug discovery is a slow and expensive process. By conservative
estimation, it takes at least 10–15 years and USD 500 million to
USD 2 billion to bring a single drug to market [1]. Although the
research on drug development has increased signiﬁcantly in recent
years, the number of new therapeutic chemical and biological enti-
ties approved by the United States Food and Drug Administration
(US FDA) has been declining since the late 1990s. There are two
most important reasons for drugs fail clinical trials: (1) lack of efﬁ-
cacy; (2) adverse side-effect. And each of these two reasons
accounts for around 30% of clinical trials failures [2]. Therefore it
is highly desirable to develop tools that can predict drug therapeu-
tic indications and side-effects accurately.
Therapeutic indication is a valid reason to use a certain medica-
tion. Inferring potential novel therapeutic indications for new or
approved drugs is one important problem in drug development.
Accurate indication prediction can drastically reduce the risk ofattrition in clinical phases. In recent years, a number of computa-
tional methods have been developed to predict drug indications
including.
 Inferring novel drug usage based on shared treatment proﬁle
using a network-based, guilt-by-association method [3].
 Predicting drug indications using their chemical structures [4].
 Inferring drug indications from protein targets interaction net-
works [5,6].
 Identifying relationships between drugs based on the similarity
of their phenotypic proﬁles (e.g., side-effects [7,8] and connec-
tive map gene expression [9,10]).
 Integrating multiple information (e.g., chemical, biological, or
phenotypic information) of drugs and diseases to predict drug
indications [11–13].
With the exception of Yang et al. [8] which used side-effects,
these strategies focus primarily on using preclinical information.
However, clinical therapeutic effects are not always consistent
with preclinical outcomes.
Drug side effect is a secondary, typically undesirable effect of a
drug or medical treatment. Predicting drug side-effects, or adverse
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According to the statistics, serious drug side-effects has been the
fourth leading cause of death in US, resulting in 100,000 deaths
per year [14]. One approach for identifying potential adverse drug
side-effects is preclinical in vitro safety proﬁling, which tests com-
pounds with biomedical and cellular assays. However this experi-
mental methodology is very expensive and labor intensive.
Therefore, developing effective computational methods for accu-
rate drug side-effect prediction is of vital importance. There have
been some prior studies on this topic, which can be categorized
into three classes:
 Linking drug side-effects to their chemical structures [15–17],
following the spirit of QSAR (quantitative structure–activity
relationship).
 Relating drug side-effects to its protein targets [18,19] because
drugs with similar in vitro protein-binding proﬁles tend to exhi-
bit similar side-effects.
 Predicting drug side-effects by integrating multiple data
sources (e.g., chemical, biological, or phenotypic properties)
[20–22].
From these existing studies we can see that, although therapeu-
tic indications and side-effects are both measurable behavioral or
physiological changes in response to the treatment, they have
mostly been researched independently in the past. Intuitively, if
drugs treating a disease share some common side-effects, this
could suggest some underlying mechanism-of-action (MOA) link-
age between the indicated disease and the side-effects. Moreover,
many side effects are extensions of a drug’s intended phenotypic
effect (e.g., hyper- and hypo-tension), so it is logical that there is
a correlation between indication and side effect. However, there
is a lack of systematic study on exploring the associations between
drug therapeutic indications and side-effects, which could be of
broad interests in drug development and repositioning.
In this paper, we conducted a comprehensive investigation on
building effective computational models for predicting drug thera-
peutic-indications and drug side-effects. We compared the predic-
tive power of different sources of information (drug chemical
structure, protein target, as well as disease indication and side-
effects themselves), which shows that, indeed, drug side-effects
and therapeutic indications are strong predictors of each other.
This conﬁrms the hypothesis that there exist strong associations
between drug indications and side-effects. To quantize the
strength of those associations, we performed Fisher’s exact test
with the prediction results [23]. Note that some preliminary eval-
uations on known associations between drug indications and side-
effects are presented in our conference paper [24]. In this paper, we
did a much more thorough investigation on all possible (both
known and unknown) drug indication and side-effects associa-
tions. We also built a visualization tool to facilitate the user’s
exploration of those detected associations, which can be used to
provide repositioning hypotheses (e.g., drugs causing postural
hypotension are potential candidates for hypertension), as well
as adverse-effect watch lists (e.g., drugs for heart failure possibly
cause impotence).
The key differences between this paper and prior studies are:
 We evaluate effectiveness of both drug therapeutic indications
and side-effects when predicting each other. Most prior work
does not explicitly leverage the relationship between indica-
tions and side-effects, in combination with other drug proper-
ties. The prior work that is most closely associated with ours
is Yang et al. [8]. However they used side-effects alone to
predict drug indications. Moreover, their approach was only
evaluated on a small data set (145 diseases and 584side-effects). The data set we used in this paper is much larger,
which includes 719 diseases and 1385 side-effects.
 We build disease-side-effect proﬁles to elucidate interesting
relationships between drug side-effects and therapeutic indica-
tions with clinical implications, which provides a systematic
way to generate drug indication hypotheses and adverse-effect
watch lists. To the best of our knowledge, there is no prior work
on this topic.
 We propose a novel visualization approach to support the inter-
active exploration of indication and side-effect associations in
the form of a dynamic bi-partite graph.
The rest of this paper is organized as follows. In Section 2 we
will introduce the details of the data set we used for this study.
The methodology is presented in Section 3, followed by the exper-
imental results in Section 4. Finally we will conclude in Section 5.2. Data set
We performed our study on approved drugs from DrugBank
[25], which is a widely used public drug information database.
From DrugBank, we collected 1447 FDA-approved small-molecule
drugs, and mapped them to PubChem [26] to get their chemical
structure information. After matching by the DrugBank provided
PubChem Compound ID for the drugs, we extracted chemical struc-
tures of the 1103 drugs. To encode the drug chemical structure, we
used a ﬁngerprint corresponding to the 881 chemical substructures
deﬁned in the PubChem. Each drug was represented by an 881-
dimensional binary proﬁle, within which the entry is 1 if the corre-
sponding PubChem substructure is present, otherwise it is 0. Take
the drug calcium as an example, its chemical formula is just Ca,
which only meets the requirement of the bit 52 (>¼1 Ca). Thus
drug calcium only has 1 association with chemical substructures
>¼1 Ca. Similarly, aspirin has 115 associations with chemical sub-
structures, ibuprofen has 84 associations with chemical substruc-
tures. A description of the 881 chemical substructures can be
found at the website of PubChem (http://pubchem.ncbi.nlm.nih.
gov/). Adding up together, we identiﬁed 132,092 associations
between drugs and chemical substructures in the dataset, i.e., each
drug has 119.8 substructures on average.
From DrugBank, we can also obtain the protein target informa-
tion for each drug. To facilitate collecting such information, we
mapped those target proteins to UniProt Knowledgebase [27], a
central knowledgebase including the most comprehensive and
complete information on proteins. After matching with the Drug-
Bank provided UniProt ID for the drugs, we extracted 3152 rela-
tionships between 1007 drugs and 775 protein targets, so each
drug has 3.1 protein targets on average. Similar to the chemical
structure representation, each drug was represented by a 775-
dimensional binary proﬁle whose elements encode the presence
or absence of their corresponding target proteins.
The third type of information we are interested in is drug side-
effects. We extract side-effect keywords from the SIDER database
[28], which contains information about medicines that are in mar-
ket and their recorded adverse drug reactions. SIDER uses STITCH
compound ids as its drug id, but can be easily matched to PubChem
Compound ID via this rule (ftp://sideeffects.embl.de/SIDER/2012-
10-17/README). This dataset contains 888 small-molecule drugs
and 1385 side-effect keywords. Similar to the representations we
mentioned above, each drug can be represented by a 1385-dimen-
sional binary proﬁle whose elements encode the presence or
absence of each side-effect keyword. We plotted the cumulative
counts of side-effect data in Fig. 1, from which we can observe that
1.69% of drugs have between 10 and 100 different side effects; 22%
of drugs have more than 100 side-effects; only 9% of drugs have
Fig. 1. Cumulative count information of the side-effect dataset. (a) The number of side-effects per drug. (b) The number of drugs per side-effect.
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occur for less than 10 drugs; 32% of all side-effects occur for 10–
100 drugs; 12% of all side-effects occur in more than 100 drugs
(Fig. 1(b)). Altogether, there are 61,102 associations between drugs
and side-effect terms in the dataset, so each drug has 68.8 side-
effects on average.
The ﬁnal piece of information we need to collect is drugs’ ther-
apeutic indications. These were obtained on extracting treatment
relationships between drugs and diseases from the National Drug
File-Reference Terminology (NDF-RT), which is part of the Uniﬁed
Medical Language System (UMLS) [29]. This drug-disease treat-
ment relationship list is also used by Li et al. [12] as the golden
standard set of a drug repositioning study. The drug names in this
list were DrugBank generic names, thus can directly be matched to
the drugs from DrugBank. From the drug-disease treatment rela-
tionship list, we extracted 3250 treatment relationships between
799 drugs and 719 diseases. Thus each drug was represented by
a 719-dimensional binary proﬁle whose elements encode the pres-
ence or absence of each of the therapeutic indications. We plotted
the cumulative count statistics of therapeutic indications data in
Fig. 2. Most of drugs (75%) treat less than 5 indicated disease;
18% of drugs treat 5–10 diseases; only 7% of drugs treat more than
10 diseases (Fig. 2(a)). 80% Of the diseases have less than 5 drugs;Fig. 2. Cumulative count information of the therapeutic indication dataset. (a) The num
indication.10% of the diseases have 5–10 related drugs; and the remaining
10% of diseases have more than 10 drugs (Fig. 2(b)).3. Methodology
In this section, we introduce the details of the methodology we
used in our study. Our method follows a very natural path on asso-
ciation study. Basically we ﬁrst test whether there exists associa-
tions between drug therapeutic indications and side-effects by
predictive modeling. If they two are both predictive to each other,
there could exist associations between them. Then we apply statis-
tical testing to obtain the signiﬁcance of the existence of those
associations. Finally we will show those signiﬁcant associations
on a user interface to facilitate the user’s exploration. Fig. 3 pro-
vides a graphical illustration on the overall method ﬂow, which
include three phases: (I) predictive modeling for drug therapeutic
indications, side-effects and various information sources; (II)
Association analysis between drug therapeutic indications and
side-effects with Fisher’s exact test based on the prediction results
from phase I; (III) Visualization of the discovered associations to
facilitate interactive exploration. In the following we describe each
phase in detail.ber of therapeutic indications per drug. (b) The number of drugs per therapeutic
Table 2
Contingency table.
Indication A No indication A
Side-effect B a b
No side-effect B c d
Fig. 3. The complete ﬂowchart of our study, which include three phases: (I) predictive modeling for drug therapeutic indications and side-effects; (II) indication/side-effects
association study from the predictive modeling results with Fisher’s exact test; (III) visual exploration of the detected associations.
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In the predictive modeling phase, we treat both drug therapeu-
tic indication and side-effect prediction tasks as binary classiﬁca-
tion problems. For disease indication, we constructed a binary
classiﬁer using logistic regression for each of the 719 diseases.
The input of every classiﬁer is the drug related information. The
output is the probability that the drug will have the corresponding
disease therapeutic indication. Similarly, for side-effect prediction,
we constructed a binary classiﬁer with logistic regression for each
of the 1385 side-effects. Our implementation uses Python 2.7 and
the source codes of each of the four classiﬁers are available in the
Scikit-Learn package [30] (http://scikit-learn.org/stable/). The
model parameters are tuned with 10-fold cross validation.
We measure the ﬁnal classiﬁcation performance using three cri-
teria: sensitivity, speciﬁcity, and area under the Receiver Operating
Characteristic curve (AUC). In order to deﬁne those criteria, we
construct the classiﬁcation confusion matrix for binary classiﬁca-
tion problems as in Table 1, where the two classes are indicated
as positive or negative. Then sensitivity is the true positive rate
computed as TP/(TP + FN). Speciﬁcity is calculated as TN/(TN + FP),
which is equal to one minus False Positive Rate. AUC score is the
area under the ROC curve, which is a graphical plot of true positive
rate vs. false positive rate. The whole ROC curve can be plotted by
varying the threshold value for prediction score, above which the
output is predicted as positive, and negative otherwise. The AUC
score has been widely used as a classiﬁcation performance mea-
sure in biomedical informatics [31]. After obtaining the AUC scores,Table 1
Confusion matrix.
Predicted valuenactual value True False
Positive TP FP
Negative TN FNwe can get the optimal cut-off point by maximizing the corre-
sponding sum of sensitivity and speciﬁcity scores.2
3.2. Association analysis
After the predictive modeling procedure in phase I, association
analysis is performed to capture the correlations between drug
therapeutic indications and side-effects. In order to achieve this
goal, we adopted Fishers exact test [23], which is a widely used
approach for measuring the signiﬁcance of the association between
two nominal variables. For example, to test the signiﬁcance of the
association between drug therapeutic indication A and drug side-
effect B, we ﬁrst construct a 2  2 contingency table shown in
Table 2, where a indicates the number of drugs that has indication
A and side-effect B simultaneously according to our prediction
from phase I; b indicates the number of drugs that does not have
indication A but has side-effect B; c the number of drugs that has
indication A but does not have side-effect B; d indicates the num-
ber of drugs that does not have either indication A or side-effect B.
Then we can use the ﬁsher_exact function in the statistics package
in Scipy3 to perform Fisher’s exact test and get the p-value of the sta-
tistical testing of the association between indication A and
side-effect B, the smaller the p-value, the stronger the association
is. This test is repeated for all possible pairs of drug indication and
side-effect.2 http://www.medicalbiostatistics.com/roccurve.pdf.
3 http://docs.scipy.org/doc/scipy/reference/generated/scipy.stats.ﬁsher_exact.
html#scipy.stats.ﬁsher_exact.
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The strengths of all potential associations between drug indica-
tions and side-effects are then fed to the visual interface we devel-
oped to facilitate the user’s interactive exploration. The visual
interface is based on a dynamic bipartite graph layout strategy. It
is bipartite because there are two types of nodes, drug therapeutic
indications and side-effects, and the edges correspond to the dis-
covered associations between them. Attached to each association
there is a strength score (which is represented by the p-value of
Fisher’s exact test, The smaller the p-value the stronger the associ-
ation). These strength scores can be used to support dynamic ren-
dering of the graph. A sliding bar is provided which the user can
use to adjust the association strength threshold: only the associa-
tions whose p-values are below the threshold will be shown. As the
user drags that bar, the bipartite graph will change accordingly. We
developed a novel methodology to make that change as smooth as
possible for visual consistency. Fig. 4 gives an overview of the
interface.
The dynamic bi-partite graph layout is based on an optimiza-
tion approach designed to ensure smooth transition between graph
renderings resulting from different association strength thresh-
olds. Speciﬁcally, in order to help maintain a user’s mental map,
successive layouts of similar graphs when we tune the threshold
should have minimal changes (stability). Furthermore, each of such
layouts should still effectively convey the characteristics of the
underlying graph (readability). Thus, our goal is to produce a
sequence of graph layouts that optimize both the stability and
readability of the resulting visualization. To achieve this goal, we
developed a spectral layout algorithm.
Given a dynamic graph Gt ¼ hVt ; Eti at time t, consisting of a set
of nodes Vt and links Et , we deﬁne an energy function to model the
desired graph layout as follows:min
X
i<j
xijaðjjXi  Xjjj  dijÞ2 þ
X
i2Ck
ð1 aÞ Xi  X 0i
 2" # ð1Þ
where X0i and Xi represent the previous and new position of node
v i 2 Vt , respectively. The ﬁrst term of the objective in Eq. (1) is from
the Kamada and Kawai method [32], which maximizes the readabil-
ity of a graph visualization by preserving the pairwise distances,Fig. 4. An overview of our visualization system, which consists of three parts: (I) the gen
(blue); (II) a sliding bar for adjusting the signiﬁcance threshold (p-value) for showing th
nodes (the user can select a group of nodes with mouse and their descriptions will b
indications and side-effects under the current signiﬁcance level, where any edge indicate
(For interpretation of the references to colour in this ﬁgure legend, the reader is referrewhere dij is the shortest distance between two nodes v i and v j.
The second item, which we have added, attempts to minimize the
changes in successive layouts.
Instead of stabilizing all the unchanged nodes (which consists
of a set U), we extract a representative set of unchanged nodes
Ck 2 U to improve the performance of the algorithm using the
method we proposed in [33]. The ﬁnal layout model is constructed
by optimizing Eq. (1) with a spectral method. Here a 2 ð0;1Þ is the
weight that is dynamically computed to achieve the desired bal-
ance between readability and stability. An online demo of such
user interface with our data can be found on http://nancao.org/
demos/druggraph/.4. Experimental results and discussion
In this section we present details of the experimental results on
our data set introduced in Section 2. All data sets used in our exper-
iments are available at http://astro.temple.edu/tua87106/
druganalysis.html.
4.1. Prediction results
As introduced in Section 3, we have two tasks in the predictive
modeling phase. For therapeutic indication prediction, we tested
the following information combination as input: (1) chemical struc-
tures (881 dimensional); (2) protein targets (775 dimensional); (3)
side-effects (1385 dimensional); (4) chemical structures + protein
targets (881 + 775 dimensional); (5) chemical structures + side-
effect (881 + 1385 dimensional); (6) protein targets + side-effect
(775 + 1385 dimensional); (7) chemical structures + protein tar-
gets + side-effect (881 + 775 + 1385 dimensional).
For side-effect prediction, we tested the following combination
as input: (1) chemical structures (881 dimensional); (2) protein
targets (775 dimensional); (3) therapeutic indications (719 dimen-
sional); (4) chemical structures + protein targets (881 + 775
dimensional); (5) chemical structures + therapeutic indications
(881 + 719 dimensional); (6) protein targets + therapeutic indica-
tions (775 + 719 dimensional); (7) chemical structures + protein
targets + therapeutic indications (881 + 775 + 719 dimensional).
Besides those different feature combinations, we also applied a
random assignment procedure as baseline, where we used the 0/1erated bipartite graph of the drug therapeutic indications (orange) and side-effects
e discovered associations; (III) a text box displaying the descriptions of the selected
e depicted in this box). The clusters in the graph are connected drug therapeutic
s an association whose signiﬁcance is larger than the threshold speciﬁed sliding bar.
d to the web version of this article.)
Table 3
Performance comparison of drug therapeutic-indication prediction with different
information sources.
Information source AUC Sensitivity Speciﬁcity
Random 0:5000 0:0010 0:0072 0:0021 0:9929 0:0002
Chemical 0:8148 0:0019 0:5321 0:0046 0:9647 0:0004
Protein 0:8011 0:0021 0:5387 0:0038 0:9841 0:0002
Side-effect 0:8408 0:0036 0:5575 0:0046 0:9737 0:0004
Chemical + Protein 0:8295 0:0021 0:4014 0:0041 0:9921 0:0001
Chemical + Side-effect 0:8563 0:0022 0:6228 0:0071 0:9516 0:0006
Protein + Side-effect 0:8515 0:0053 0:5625 0:0070 0:9793 0:0003
Chemical + Protein +
Side-effect
0:8640 0:0035 0:6195 0:0067 0:9650 0:0004
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example, if the ratio in the given training data is 90%, we can assign
zero to 90% of examples in test, and the rest to 1. This baseline is
implemented for both indication prediction and side-effect predic-
tion tasks.
We used 10-fold cross validation to evaluate the performance of
all methods. For each fold, we held out all the associations involved
with 10% of the drugs. For both indication prediction and side-
effect prediction tasks, the sample sizes of output classes are highly
imbalanced (negative class dominates). Consequently, the perfor-
mance of the prediction could be overestimated. To alleviate this
problem, we incorporated a sample balancing strategy in the 10-
fold partitioning procedure, where all drugs were split into 10
equal-sized subsets, and each subset was used in turn as the test-
ing set. For constructing the training set at each round of cross val-
idation, we used all the positive drug-indication or drug-side-effect
pairs from the remaining nine subsets, and randomly selected neg-
ative pairs from the same nine subsets, whose amount is twice as
large as the positive pair number. The same strategy was also used
in Gottlieb et al. [11]. To obtain robust results, we performed 10
independent cross-validation runs, in each of which a different
random partition of the data set to 10 parts was used; we then
computed the mean and the standard deviation of the evaluation
scores over the entire 10 repetitions. To conduct a fair and accurate
comparison across different data sources, we only considered the
drugs which have all available sources for each task.
To evaluate the global performance across 719 diseases (for
drug indication prediction) and 1385 side-effects (for drug side-
effect prediction), we concatenate the prediction scores of all drugs
over all diseases for drug indication prediction and draw a global
ROC curve based on those scores. Then we compute the AUC value
based on this overall ROC curve. Similar for side-effects prediction.
This strategy has also widely been used in the past for both drug
indication prediction tasks [11,12] and side-effect prediction tasks
[16,22]. The reported sensitivity and speciﬁcity were obtained
from the operating points of the global ROC curve, so that it gives
the best tradeoff between false positives and negatives.
Fig. 5 summarizes the average ROC curves of 10 runs of the
cross validation for different information sources for therapeutic
indication prediction, and Table 3 summarizes the evaluation
results. From those results we can see that when the information
sources were compared independently, side-effect is the mostFig. 5. The averaged ROC comparison of therapeutic indication predictions for
various information source combinations using in 10-fold cross validation. Infor-
mation sources are sorted in legend of the ﬁgure according to their AUC score.informative (AUC of 0.8408), chemical structure ranks as the sec-
ond (AUC of 0.8148), followed by target protein information
(AUC of 0.8011). Overall, combining any two data sources improves
the AUC, and adding side-effects works better than without it. The
highest AUC score (AUC of 0.8640) is obtained by combing all three
data sources.
Similarly, Fig. 6 shows the average ROC curves of 10 runs of the
cross validation for different information sources for side effect
prediction, and Table 4 summarizes the results. When the informa-
tion sources were compared independently, therapeutic indication
is the most informative (AUC of 0.7058), target protein information
is also highly informative (AUC of 0.6993), but chemical structure
performed much worse (AUC of 0.6379). This could be partially
explained with the following reasons. Both therapeutic indicationsFig. 6. The averaged ROC comparison of therapeutic indication predictions for
various information source combinations using in 10-fold cross validation. Infor-
mation sources are sorted in legend of the ﬁgure according to their AUC score.
Table 4
Performance comparison of drug side-effects prediction with different information
source.
Information source AUC Sensitivity Speciﬁcity
Random 0:5001 0:0004 0:0599 0:0007 0:9403 0:0004
Chemical 0:6379 0:0008 0:2436 0:0012 0:9401 0:0003
Protein 0:6993 0:0014 0:4746 0:0010 0:9128 0:0006
Indication 0:7058 0:0014 0:5207 0:0017 0:8995 0:0005
Chemical + Protein 0:6644 0:0009 0:2843 0:0016 0:9468 0:0003
Chemical + Indication 0:6690 0:0012 0:2881 0:0016 0:9494 0:0004
Protein + Indication 0:7103 0:0011 0:4689 0:0018 0:9319 0:0002
Chemical + Protein +
Indication
0:6837 0:0010 0:3035 0:0015 0:9542 0:0003
Fig. 7. Cumulative counts of the highly correlated disease-side-effect pairs result (p-value less than 0.01). (a) The number of side effects per disease (therapeutic indication).
(b) The number of diseases (therapeutic indications) per side effect.
F. Wang et al. / Journal of Biomedical Informatics 51 (2014) 15–23 21and side-effects are complex phenomenological observations that
attributed to chemical structures (i.e., drugs) interact with primary
or additional targets (off-targets hereafter). Expected activities
derived from on-targets result in therapeutic effects. Unexpected
(usually unwanted and harmful) activities derived from off-targets
lead to side-effects. Minor differences in chemical structure of a
drug may not affect the primary targets, therefore chemical struc-
ture could be very useful for predicting drug indications. However,
even minor differences in chemical structure of a drug may cause a
dramatic impact on how it interacts with off-targets, thus could
result in signiﬁcant differences in side-effect proﬁles of the drug.
Therefore, drugs with similar chemical structures may not have
similar side-effects, i.e., the performance could be bad if we use
chemical structure to predict side-effects. While combing thera-
peutic indication and target protein results in the highest AUC
score (AUC of 0.7103), combining chemical structure and any other
information sources actually makes the prediction performance
worse.Table 5
10 Most correlated side-effects for disease hypertension and pain.
Disease Side-effects P-value
Hypertension Claudication 1.36E23
Impotence 5.20E17
Postural hypotension 4.33E14
Cold extremities 6.25E14
Gout 4.72E12
Pemphigus 4.94E12
Syncope 5.17E08
Weakness 4.52E07
Hyperuricemia 7.20E07
Vertigo 2.05E06
Pain Hallucinations 3.78E05
Heart block 5.66E05
Tachycardia 1.08E04
Apnea 7.57E04
Forgetful 1.19E03
Ventricular extrasystoles 1.85E03
Somnolence 2.79E03
Urinary retention 4.56E03
Blindness 8.11E03
Tinnitus 9.05E034.2. Association study results
From those predictive modeling results we can observe that
drug side-effects is the most predictive information for drug ther-
apeutic indications (with 0.8408 prediction AUC), and drug thera-
peutic indication is the most predictive information for drug side-
effects (with 0.7058 prediction AUC). This suggests there indeed
exists strong hidden correlations between them. To explore those
correlations, we used Fisher’s exact test as described in Section 3.2.
We built indication-side-effect proﬁles, i.e., the most likely side-
effects by the drugs which treat a speciﬁc disease, based on known
and predicted drug-disease and drug-side-effect relationships.
Among all 995,815 (719 diseases by 1385 side-effects) disease-
side-effect pairs, there are 17,386 (1.75%) pairs with p-value less
than 0.05, which is a typical threshold indicating whether a statis-
tical testing is signiﬁcant or not.
At a p-value cutoff of 0.01, we found 6706 highly correlated dis-
ease-side-effect pairs between 458 disease and 1077 side-effects.
On average, each disease’s drugs very likely to cause 14.6 side-
effects and each side-effect highly associates with 6.2 types of
diseases. We plotted the cumulative counts of highly correlated
disease-side-effect pairs (p-value less than 0.01) in Fig. 7, from
which we can observe that 63% of the diseases highly correlate
with less than 10 side-effects; 36% of the diseases highly correlate
with 10–100 drugs; only 4 diseases highly correlate with more
than 100 side-effects (Fig. 7(a)). For example, disease Obsessive–
Compulsive Disorder is highly correlated with 260 side-effectkeywords in our analysis, but only 7 drugs treat this disease in
our drug-disease dataset. 60% Of side-effects are highly associated
with less than 5 diseases; 24% of side-effects are highly associated
with 5–10 diseases; 16% of side-effects are highly associated with
more than10 diseases (Fig. 7(b)).
To better illustrate the associations we found, we provided two
concrete examples in Table 5, which are 10 most closely correlated
side-effects for diseases Hypertension and Pain. From the table we
can observe that for hypertension, some of the side-effects are
physiologically related and the mechanism of action (MOA) can
be explained. For example, some hypertension drugs may result
in a sudden drop in blood pressure when a person stands up, thus
the side-effect postural hypotension happens. Some hypertension
drugs (e.g., b-blockers) hits a-adrenergic receptors protein target
in penile tissue, which will cause side-effect impotence. The
decreased blood pressure caused by some hypertension drugs
(e.g., b-blockers) also cause side-effects syncope, vertigo, and
weakness. Side-effect pemphigus is related to ACE inhibitors,
which is also one kind of hypertension drug. Some hypertension
treatments (e.g., Diuretics) cause human body to lose salt and
water, potentially precipating side-effects gout and hyperuricemia.
Similarly, for drugs that treat pain, nonsteroidal anti-inﬂammatory
pain medicines (e.g., Ibuprofen and Celecoxib) increase risk of
heart attack and stroke, and may cause tachycardia and heart block
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drugs increase the level of certain brain chemicals, which affect
how the brain perceives pain. But they cause side-effect urinary
retention. Other types of antidepressants (e.g., SSRI and SNRI) also
cause somnolence, and delayed ejaculation.
As another example, Table 6 shows the top 10 therapeutic indi-
cations (diseases) with strongest correlation to side-effects weight
loss and impotence. For side-effect weight loss, many related dis-
eases in the list are mood disorders (e.g., bipolar disorder, depres-
sive disorder, panic disorder). The most widely prescribed mood
control drugs come from a class of medications known as selective
serotonin reuptake inhibitors (SSRIs, such as Prozac, Zoloft). SSRIs
act on serotonin, a chemical in the brain that helps regulate mood.
However, serotonin also plays a role in digestion, sleep and other
bodily functions. Thus mood control drugs result in dizziness, nau-
sea, loss of appetite, and ﬁnally cause weight loss. Similarly, the
drugs for Alzheimer disease (e.g., Aricept, Cognex, Exelon) cause
vomiting, nausea, loss of appetite, thus result in weight loss. ForTable 6
10 Most correlated indicated diseases for side-effect weight loss and impotence.
Side-effect Disease P-value
Weight loss Bipolar disorder 6.54E07
Breast neoplasms 1.66E06
Alzheimer disease 8.23E06
Panic disorder 5.16E05
Epilepsies, partial 1.02E04
Colorectal neoplasms 1.09E04
Attention deﬁcit disorder with hyperactivity 1.17E04
Diarrhea 1.59E04
Depressive disorder 6.06E04
Asthma 3.91E03
Impotence Hypertension 5.20E17
Heart failure 1.01E08
Diabetic nephropathies 4.61E08
Depressive disorder 2.22E07
Urinary tract infections 5.16E06
Bipolar disorder 3.56E05
Schizophrenia 3.56E04
Angina pectoris 6.81E04
Asthma 2.14E03
Myocardial infarction 7.99E03
Fig. 8. An example clique of drug theraside-effect impotence, drugs for cardiovascular diseases (e.g.,
hypertension, heart failure) appear on the list, because they can
lower the pressure inside blood vessels, so the heart does not have
to work as hard as usual to pump blood throughout the body. How-
ever, the decreased blood ﬂow can reduce desire and interfere with
erections and ejaculation, thus cause impotence. Some cardiovas-
cular drugs limit the availability of cholesterol and likely interfere
with the production of testosterone, estrogen and other sex hor-
mones, also cause impotence. Drugs for mood disorders (e.g.,
depressive disorder, bipolar disorder) are on the list as well
because they will block the action of brain chemicals that relay sig-
nals between nerve cells, thus decrease sex drive, causing impo-
tence as a side-effect.
Both therapeutic indications and clinical side-effects are human
phenotypic data obviating translation issues. Therefore, those
strongly correlated disease-side-effect pairs are beneﬁcial for drug
discovery in the following sense.
 We could use the side-effects information to generate hypothe-
ses for repurposing existing treatments. For example, based on
the information of Table 5, we may consider drugs with side-
effect postural hypotension as candidates for treating hyperten-
sion. Also based on the information in Table 6, we may consider
and evaluate some mood-disorder drugs for the usage of weight
loss (i.e., as weight-loss pills).
 If a new treatment is designed for a speciﬁc disease, all health
care stakeholders (e.g., regulators, providers, patients and phar-
maceutical companies) should pay more attention to adverse
reactions in the associated side-effect list of the disease (e.g.,
Table 5 for hypertension and pain), and control the formulation
and dosing of drugs in the clinical trials to prevent serious
safety issues.
4.3. Visual exploration example
Although the discovered drug therapeutic indication and side-
effect associations are informative, it would be very difﬁcult to
check all of them one by one on spreadsheets like Tables 5 and 6.
The visual interface introduced in Section 3.3 can be used to
explore these associations in a much more efﬁcient and effectivepeutic indications and side-effects.
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167,392 predicted associations between 567 drugs and 1262
side-effect terms, and 22,639 predicted associations between 567
drugs and 612 indications. Then we combine both predicted and
ground truth indication-side-effects associations and use Fisher’s
exact test to obtain all their p-values.
We demonstrate those discovered associations in our visualiza-
tion system and show an example clique in Fig. 8, where there are
four diseases: Diabetic Nephropathies, Heart Failure, Hypertension,
and Ventricular Dysfunction. The last three are cardiovascular dis-
eases, and Diabetic Nephropathies is a common comorbidity and
one of the causes of cardiovascular diseases. This clique also con-
tains 30 highly correlated side-effects. Some of the side-effects
are physiologically linked to the cardiovascular diseases and the
mechanism of action (MOA) can be explained. For example, some
hypertension drugs may result in a sudden drop in blood pressure
when a person stands up, thus the side-effect postural hypotension
happens. Some cardiac drugs (e.g., b-blockers) hits a-adrenergic
receptors protein target in penile tissue, which will cause side-
effect impotence. The decreased blood pressure caused by some
cardiac drugs (e.g., b-blockers) also cause side-effects cold extrem-
ities, dizziness, vertigo, and weakness. Side-effect pemphigus is
related to ACE inhibitors, which may induce an autoimmune
response to skin proteins. Some popular cardiac medications
(e.g., Diuretics) cause human body to lose salt and water, poten-
tially precipitating side-effect gout.
5. Conclusion
In this paper, we described a systematic study on the explora-
tion of multiple sources of information (and their combinations)
for therapeutic-indication and drug side-effect predictions. We
found that side-effect and therapeutic indication are most predic-
tive factors for each other, thus conﬁrming that there exist strong
association between drug indications and side effects. Further-
more, we performed statistical testing to obtain the strength of
the discovered associations and developed a novel visual interface
to facilitate the interactive exploration of these associations in a
dynamic and comprehensive manner. These ﬁndings and tools
could provide a powerful mechanism for hypothesis generation,
which can be used to improve the drug development process via
better targeted trial designs.
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